A detailed history of Marshall Wace, LLP transactions in Vaxart, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 247,414 shares of VXRT stock, worth $202,879. This represents 0.0% of its overall portfolio holdings.

Number of Shares
247,414
Previous 533,079 53.59%
Holding current value
$202,879
Previous $693,000 76.19%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.53 - $1.3 $151,402 - $371,364
-285,665 Reduced 53.59%
247,414 $165,000
Q1 2024

May 15, 2024

BUY
$0.56 - $1.41 $298,524 - $751,641
533,079 New
533,079 $693,000

Others Institutions Holding VXRT

About Vaxart, Inc.


  • Ticker VXRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,506,000
  • Market Cap $104M
  • Description
  • Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...
More about VXRT
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.